Vaccines and diagnostic sales underpin Novartis's first half
This article was originally published in Scrip
Executive Summary
Novartis's pharmaceutical sales grew by 10% in the first half, reaching $13.2 billion, while vaccines and diagnostic sales increased by 25% to $602 million and sales of generics reached $3.8 billion (+13%).